Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-2006
- Development stage
- Preclinical
- Lead developer
- G2GBio
- Modality
- Small Molecules
- Administration
- Local Infiltration, Subcutaneous
01
Overview
GB-2006 is a long-acting, sustained-release injectable formulation of bupivacaine being developed by G2G Bio for the management of post-operative pain in veterinary medicine. The drug utilizes G2G Bio's proprietary InnoLamp (Innovative Long-Acting MicroParticle) technology, which encapsulates the local anesthetic within biodegradable PLGA (poly lactic-co-glycolic acid) microparticles. This formulation is designed to provide a controlled, extended release of bupivacaine at the surgical site, offering prolonged local analgesia and reducing the need for systemic pain management, such as opioids, in animals following surgery.
- Other names
- G2G Bio Veterinary Post-Operative Pain TreatmentG-2G Bio Veterinary Post-Operative Pain TreatmentG 2G Bio Veterinary Post-Operative Pain Treatment
Beyond the preview
Go deeper on GB-2006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-2006.